IP in M&A: Get your rights in order

A company's brand value and/or its product or innovation portfolio are key value differentiators, providing plenty of strategic reasons for merger or acquisition (M&A) activity. However, transferring and updating IP ownership is rarely a simple procedure. In this white paper, we set out common pitfalls and the key steps for success.

A well-maintained IP portfolio and, just as importantly, a well-maintained record of the IP portfolio can add significant value to a company, as well as making it an attractive proposition. From a buyer’s perspective, it can make the transition from buyer to owner a smoother ride.

In an ideal world, the IP portfolio will have been diligently maintained and recorded, and an acquired company’s IP audited and cleansed as part of the build up to the M&A activity; however, such due diligence does not always take place, whether due to time constraints or the nature of the acquisition. For that reason, IP professionals can often find themselves on the back foot when managing such transactions, with the volume and complexity of the  transfer and updating process, as well as the time, cost and resource demands of the workload, misunderstood. In this white paper, we set out specific guidance for managing IP during M&A activity, from pre-completion due diligence to managing deadlines and paper work.

Please download the white paper below for best practice guidance on managing IP following M&A.

Please contact us for further information

Contact us

Insights liés

Articles

Oncologie : l'Europe excelle en stratups mais peine à s'imposer dans l'innovation de pointe

L'Office européen des brevets (OEB) a publié le mois dernier sa deuxième étude en matière d’innovation dans les technologies anticancéreuses. Selon cette étude, l'Europe est en tête en nombre de startups dédiées à l'oncologie mais recule face aux États-Unis et à la Chine dans les domaines technologiques les plus innovants contre le cancer, notamment en immunothérapie cellulaire, thérapie génique et analyse d’images. Par ailleurs, la recherche publique joue un rôle central dans l’innovation oncologique européenne, la France se distinguant particulièrement avec l’INSERM et le CNRS, classés deuxième et troisième mondialement pour les dépôts de brevets liés au cancer.

Par Nadège Lagneau,
Oncologie : l'Europe excelle en stratups mais peine à s'imposer dans l'innovation de pointe

Pour plus d'informations ou de conseils contactez-nous